Clinical Trial Update: HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

Clinical trial update for HepNet Acute HCV IV using Ledipasvir/Sofosbuvir in acute genotype 1 HCV infection; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

Sponsor: HepNet Study House, German Liverfoundation | Conditions: Acute Hepatitis C | Phase 2 | Status: COMPLETED